Swedish companies internationally connected – Atrogi receives major Korean investment

Encouragingly, the pipeline report shows a high degree of international connectivity among Swedish companies.

One such example is SwedenBIO member Atrogi, which has just completed a new share issue of SEK 90 million. The anchor investors include Korea’s largest private equity firm, Korea Investment Partners.

What does the investment mean for you? And where does it come from?

-“We see the fact that such an established player as Korea Investment Partners is investing in us as strong evidence of our research and the market potential of the drug we are developing. To do so in the middle of the corona crisis is a sign of strength,” says the company’s CEO Alexandra Ekman Ryding.

Atrogi is developing a new drug for type 2 diabetes. Preclinical trials have shown several positive effects beyond the primary goal of lowering the patient’s blood sugar.

-Thanks to the capital injection, we are now planning for a Phase I clinical trial in 2021. This is a major and important step in the process of developing a new class of oral diabetes medicine.

Read more in the press release.